CLEO Diagnostics Ltd. is a medical diagnostics/devices company which mainly focuses on the development of non-invasive blood based IVD tests to detect the presence, and recurrence, of ovarian cancer. The company developed a three-phased product development strategy that will deliver three related tests for ovarian cancer detection: Triage Test-a pre-surgical test, Recurrence Test-a post-surgical test and Screening Test-a screening test to identify early-stage ovarian cancer. CLEO Diagnostics was founded on November 30, 2021 and is headquartered in Melbourne, Australia.